Skip navigation
Watchlist Sponsored By :


Current DateTime: 07:01:55 14 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 07:01:55 14 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 07:01:55 14 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
By: Peter Kang | 04 Jun 2007 | 04:27 PM ET
Text Size

Onyx Pharmaceuticals [ONXX  Loading...      ()   ] was the big winner at the annual meeting of the American Society of Clinical Oncology, or ASCO, held in Chicago. Onyx shares rose more than 8% on Monday after the company announced positive results for cancer drug Nexavar.

The Emeryville, Calif.-based company and marketing partner Bayer said liver cancer patients taking Nexavar extended survival rates by about three months compared to those taking a placebo, according to data from a recent clinical trial. The drug is already approved for the treatment of kidney cancer.

Bear Stearns upgraded the Onyx shares to "outperform" from "peer perform" and raised the price target to $40. Analyst Akhtar Samad said in a note sent to clients that results of the trial made him more confident Nexavar will become the "standard of care" in hepatocellular carcinoma, a form of liver cancer and fifth most common type of cancer overall.

Biotech giant Genentech [DNA  Loading...      ()   ] reported new data for cancer drug Avastin below expectations, sending shares down 1.95%. Avastin failed to show an overall survival benefit in colon cancer patients taking the drug along with the most commonly used chemotherapy, according to a clinical trial known as AVAiL. "Data from the AVAiL trial were disappointing in terms of Avastin's activity, and will likely drive physicians to the lower dose of the drug over time," said Bret Holley, an analyst with CIBC World Markets.

Pfizer [PFE  Loading...      ()   ] reported promising resutls for experimental pancreatic cancer treatment axitinib. The world's largest drugmaker said data from an early Phase II trial was strong enough to warrant further studies.

Celgene [CELG  Loading...      ()   ] shares fell slightly after the biotech firm announced new data for Revlimid in first-line multiple myeloma in line with expectations. Celgene said 96% of patients taking Revlimid and low dose dexamethasone, a steroid, survived for one year, a greater percentage than any other previous first-line trial.

Shares of both SuperGen [SUPG  Loading...      ()   ] and MGI Pharma [MOGN  Loading...      ()   ] rose following lukewarm data for rival treatments of Dacogen, the companies' drug for myelodysplastic syndrome, or MDS. Data for competitive products Pharmion's Vidaza and Celgene's Revlimid appeared inferior to Dacogen, said Vinny Jindal, an analyst with ThinkEquity Partners. "We believe Dacogen will emerge as the front-line standard of care for higher-risk MDS patients, with Vidaza or Vidaza plus Revlimid used in Dacogen-failures," he wrote in a client note.

Shares of ImClone Systems [IMCL  Loading...      ()   ] fell 2.4% after the company announced mixed results for cancer drug Erbitux. The company said the drug combined with chemotherapy delayed death in patients with head-and-neck cancer by three months. "We think this is a major impact," Dr. Eric Rowinsky, ImClone's chief medical officer, told CNBC's Mike Huckman.

In addition, Erbitux, co-marketed and co-developed with Bristol-Myers Squibb [BMY  Loading...      ()   ], delayed progression of the colon cancer by one month when added to standard chemotherapy treatments, according to new data released Monday.

IDM Pharma [IDMI  Loading...      ()   ] was another winner, rising more than 16% on Monday after the tiny drug developer said data from a Phase II trial of experimental vaccine EP-2101 was shown to be well tolerated in lung cancer patients. The company said one-year survival in patients treated with the vaccine was 60% compared with 49% of patients in the control group.

ArQule [ARQL  Loading...      ()   ] released results of experimental drug ARQ 197, which showed good safety, promising activity and potential for reducing tumors. But investors appeared to be disappointed with the results, sending shares down sharply on Monday.

Shares of Telik [TELK  Loading...      ()   ] fell 22% after the company reported disappointing data for experimental lung cancer drug telcyta. A late-stage study of the drug in patients with advanced non-small cell lung cancer failed to show superiority compared with AstraZeneca's Iressa.

ASCO Winners and Losers
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Peter Kang is a markets writer with CNBC.com and can be reached at .

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:03:47 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:07:48 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:07:48 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters